|Target||interleukin 31 (IL-31)|
Lokivetmab, trade name Cytopoint, is a monoclonal antibody used to treat atopic dermatitis in dogs. It acts against interleukin 31 (IL-31), which is a cytokine involved in causing itchiness (pruritus). Lokivetmab is administered by subcutaneous injection; each dose is effective for four to eight weeks.
The United States Department of Agriculture (USDA) approved lokivetmab (manufactured by Zoetis and sold under the trade name Cytopoint) in December 2016, and it was approved by the European Medicines Agency in 2017. Lokivetmab was the first monoclonal antibody to be approved for use in animals in the European Union.
- "Zoetis earns license for Cytopoint skin therapy". Veterinary Practice News. 4 January 2017. Retrieved 2018-07-06.
- Marsella, R; De Benedetto, A (26 July 2017). "Atopic dermatitis in animals and people: an update and comparative review". Veterinary Sciences. 4 (3). doi:10.3390/vetsci4030037. PMC 5644664. PMID 29056696.
- McKay, Lindsay (13 July 2017). "Making a difference for dogs with atopic dermatitis: When to use Apoquel and when to use Cytopoint". dvm360.com. Retrieved 2018-07-07.
- "First antibody therapy in veterinary medicine launched for dogs in the UK". Veterinary Record. 181 (1): 6–7. 30 June 2017. doi:10.1136/vr.j3147.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|